Should You Invest in the Wild Swings of Organovo Holdings?
Shares of tissue engineering company OrganovoHoldings have exploded higher in the past month on heavy volume, only to suffer a swift 25% pullback on an astounding 30 million shares traded. The company only has 78 million shares outstanding. Even with the pullback, shares are up more than 50% in the past month alone.
Why did Organovo Holdings experience such a dramatic pullback? Other than the obvious fact that the company was drastically overvalued at $1 billion given limited near-term revenue possibilities, there was a post on Tuesday morning from Richard Pearson at Seeking Alpha. It's also very obvious that commercial tissue engineering technologies are still in their infancy. Any arguments pointing to the disconnection between the company's balance sheet and valuation can be summed up in much fewer words.
Any way you slice it
Take any metric you want from Organovo's income statement or balance sheet, and it quickly becomes clear that a $1 billion market cap (or even a $500 million market cap) is not based on current realities.
Value as of Sept. 30, 2013
Cash and cash equivalents
Total revenue since inception
Net loss since inception
What investors are factoring into the company's valuation is potential -- and a lot of it. Unfortunately, even when the company launches its first product, 3-D liver assays for toxicology at the end of 2014 (assuming all goes as planned), there won't be very much revenue to report. It will be a major milestone for Organovo and investors, but hardly the end of the road or one with any major financial impact. I don't think you need to invest today for fear of missing out on a greater opportunity tomorrow. Simply put, reality isn't done having its way with shares.
Getting to the facts
Pearson called out "hyper bullish articles on The Motley Fool" as one reason for the ascension of shares, but I don't think anyarticlespublished here made questionable statements or forgot to mention how distant the opportunity is for tissue engineering platforms. It's clear that the technology is overhyped and widely misunderstood. For instance, there were 7,380 words in Pearson's article, but he failed to mention "tissue engineering" -- the correct term for the technology -- even once. That's an important phrase to include in an article describing the company. Essentially, any attention given to a company that was recently added to a major exchange is bound to create a push or pull on shares.
He correctly noted that there are other, more established 3-D cell culture liver assays on the market for determining toxicology for pharmaceutical and cosmetic products. That means competition for Organovo's developmental platform, which may be news to many investors. However, several of the bioprinters Pearson mentioned require inorganic scaffolds to support tissues -- something that Organovo's NovoGen doesn't need and is one of its main advantages.
In addition, being publicly traded affords the company the opportunity to raise the large amounts of capital necessary to develop its platform. That doesn't mean the company will be wildly, mildly, or marginally successful, but it represents an advantage over less-capitalized academic research labs nonetheless.
Foolish bottom line
I think Organovo is an intriguing story, but I can't rationalize a $1 billion valuation for the company. Heck, even $500 million looks absurd to me. I am in no way supporting an investment or completely refuting Pearson's claims -- just simply pulling the conversation back to the facts. The takeaway for investors is that Organovo is overhyped and misunderstood, which has led to its severe overvaluation given current financials and near-term revenue opportunities. I will continue to encourage investors to sit on the sidelines until more certainty comes to Organovo the business, rather than gambling on its potential.
Growth that isn't all potential
Organovo Holdings has a lot of potential baked into shares, which may scare away most investors. Luckily, it is far from the only way to inject growth into your portfolio. This incredible tech stock is growing twice as fast as Google and Facebook, and more than three times as fast as Amazon.com and Apple. Watch our jaw-dropping investor alert video today to find out why The Motley Fool's chief technology officer is putting $117,238 of his own money on the table, and why he's so confident this will be a huge winner in 2013 and beyond. Just click here to watch!
The article Should You Invest in the Wild Swings of Organovo Holdings? originally appeared on Fool.com.Fool contributor Maxx Chatsko has no position in any stocks mentioned. Check out his personal portfolio or his CAPS page, or follow him on Twitter, @BlacknGoldFool, to keep up with his writing on biopharmaceuticals, industrial biotech, and the bioeconomy.The Motley Fool recommends and owns shares of Amazon.com, Apple, Facebook, and Google. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.